Actively Recruiting
Phase 2 Study of Pumitamig Combined With Chemotherapy for Adults With Untreated Metastatic Pancreatic Cancer
Led by BioNTech SE · Updated on 2026-07-28
105
Participants Needed
24
Research Sites
34 weeks
Total Duration
AI-Summary
What this Trial Is About
This trial is designed for adults diagnosed with metastatic pancreatic ductal adenocarcinoma PDAC who have not yet received systemic treatment for their advanced cancer and have a good performance status. The study evaluates pumitamig, an investigational drug, in combination with chemotherapy to assess its safety and effectiveness. This phase II trial plans to explore different chemotherapy regimens combined with pumitamig to understand their impact on the disease.
CONDITIONS
Brief Title
A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
Research Team
B
BioNTech clinical trials patient information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
